At the news
? NEUTRALIMPACT 4/10 CLUSTER filed Mar 19, 2026 at 16:30 ET
United Therapeutics insiders, including CEO Martine Rothblatt and CFO James Edgemond, conducted a series of derivative exercises and open-market sales over the past week. The total open-market sales amounted to approximately $1.07 million, with the majority tied to option exercises at low strike prices, indicating planned equity realization rather than reactive selling.
- CEO Martine Rothblatt sold 559 shares for $373,765 across multiple transactions at prices between $516.84 and $536.97.
- CFO James Edgemond sold 991 shares for $527,236; also exercised 20,000 derivative shares (10,000 at $135.42, 10,000 at $0).
- Director Tommy Thompson sold 275 shares for $147,845 and exercised 4,000 derivative shares.
- Director Judy Olian sold 200 shares for $106,000.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access